Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — Investor Presentation (November 2012)
12 slides from Ironwood Pharmaceuticals's investor presentation, Nov 6, 2012
Slide 1: P&L Presentation of LINZESS
P&L Presentation of LINZESS™ November 6, 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, the anticipated accounting structure for LINZESS™ (linaclotide) and the potential for Ironwood to achie
Slide 3: P&L Presentation of LINZESS
P&L Presentation of LINZESS Michael Higgins Chief Operating Officer Jim DeTore Vice President, Finance and Administration
Slide 4: Ironwood/Forest U.S. Collaboration
Ironwood/Forest U.S. Collaboration • 50/50 collaboration in the U.S. • Forest to record all LINZESS revenues and COGS • Forest and Ironwood to record LINZESS-related operating expenses on respective financial statements • Each quarter, LINZESS-related revenues and expenses combined in LINZESS P&L –
Slide 5: US Partnership Accounting for LINZESS (Loss)
US Partnership Accounting for LINZESS (Loss)* Commercial Pool Total LINZESS Commercial Pool Ironwood Forest Impact of Transfer Payments Financial P&L Reporting Product 100 100 Revenue Ironwood P&L Forest Ironwood COGS 20 20 P&L Forest Product Revenue Gross Margin 80 80 Product Revenue 10
Slide 6: US Partnership Accounting for LINZESS (Loss)
US Partnership Accounting for LINZESS (Loss)* Commercial Pool Total LINZESS Commercial Pool Ironwood Forest Impact of Transfer Payments Financial P&L Reporting Product 100 100 Revenue Ironwood Forest COGS 20 20 Ironwood Forest Product Revenue Gross Margin 80 80 Product Revenue 100 Collab
Slide 7: US Partnership Accounting for LINZESS (Loss)
US Partnership Accounting for LINZESS (Loss)* Commercial Pool Total LINZESS Commercial Pool Ironwood Forest Impact of Transfer Payments Financial P&L Reporting Product 100 100 Revenue Ironwood Forest COGS 20 20 Ironwood Forest Product Revenue Gross Margin 80 80 Product Revenue 100 Collab
Slide 8: US Partnership Accounting for LINZESS (Loss)
US Partnership Accounting for LINZESS (Loss)* Commercial Pool Total LINZESS Commercial Pool Ironwood Forest Impact of Transfer Payments Financial P&L Reporting Product 100 100 Revenue Ironwood Forest COGS 20 20 Ironwood Forest Product Revenue Gross Margin 80 80 Product Revenue 100 Collab
Slide 9: US Partnership Accounting for LINZESS (Profit)
US Partnership Accounting for LINZESS (Profit)* Commercial Pool Total LINZESS Commercial Pool Ironwood Forest Impact of Transfer Payments Financial P&L Reporting Product 400 400 Revenue Ironwood Forest COGS 50 50 Ironwood Forest Product Revenue Gross Margin 350 350 Product Revenue 400 Co
Slide 10: US Partnership Accounting for LINZESS (Profit)
US Partnership Accounting for LINZESS (Profit)* Commercial Pool Total LINZESS Commercial Pool Ironwood Forest Impact of Transfer Payments Financial P&L Reporting Product 400 400 Revenue Ironwood Forest COGS 50 50 Ironwood Forest Product Revenue Gross Margin 350 350 Product Revenue 400 Co
Slide 11: US Partnership Accounting for LINZESS (Profit)
US Partnership Accounting for LINZESS (Profit)* Commercial Pool Total LINZESS Commercial Pool Ironwood Forest Impact of Transfer Payments Financial P&L Reporting Product 400 400 Revenue Ironwood Forest COGS 50 50 Ironwood Forest Product Revenue Gross Margin 350 350 Product Revenue 400 Co
Slide 12: Ironwood
V/ lronwood
Ironwood Pharmaceuticals — Investor Presentation (November 2012) on 6ix